Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SET binding factor 1 (SBF1) is a large, multidomain protein encoded by the SBF1 gene located on chromosome 22q13.33, and is also known as myotubularin-related protein 5 (MTMR5)[1][2][4]. SBF1 is a member of the myotubularin family, characterized as a catalytically inactive protein tyrosine phosphatase due to missing key residues in its active site[1][6]. It has a guanine nucleotide exchange factor (GEF) domain, enabling it to activate small Rab GTPases, notably RAB28, which are involved in endolysosomal trafficking[1]. SBF1 acts as an adapter protein for the active phosphatase MTMR2, regulating its localization and function—key for processes such as autophagy and Schwann cell myelination[1]. SBF1 is predominantly expressed in the brain and skeletal muscle; its dysregulation or mutation is associated with disorders such as Charcot-Marie-Tooth disease type 4B3 (CMT4B3) and possibly late-onset neurocognitive disorders including Alzheimer’s disease[1][2][4]. SBF1 is not an established therapeutic target for any approved drugs and has no known drug interactions[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SET binding factor 1 (SBF1).